Delivering prostate cancer prevention messages to the public: How the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 4, 2004, Pages 369-376

  Croker, Kara Smigel ^a   Ryan, Anne ^a   Morzenti, Thuy ^a   Cave, Lynn ^a   Maze Gallman, Tamara ^a   Ford, Leslie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Consumer information processing; Diffusion of innovations theory; Finasteride; Media; PCPT; Prostate cancer prevention; Public health message

Indexed keywords

ALPHA TOCOPHEROL; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; TAMOXIFEN;

ALOPECIA; BREAST CANCER; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DATA BASE; E-MAIL; HEALTH CARE ORGANIZATION; HORMONAL THERAPY; HUMAN; INFORMATION DISSEMINATION; INSTRUMENTATION; INTERNET; MASS SCREENING; MEDICAL INFORMATICS; MEDICAL INFORMATION SYSTEM; POSITIVE FEEDBACK; POSTAL MAIL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; PUBLIC RELATIONS; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SOCIAL MARKETING; TELEVISION;

CLINICAL TRIALS; COMMUNICATION; COMMUNITY-INSTITUTIONAL RELATIONS; ENZYME INHIBITORS; FINASTERIDE; HEALTH POLICY; HUMANS; INFORMATION SERVICES; MALE; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT ADVOCACY; PROSTATIC NEOPLASMS; PUBLIC OPINION; PUBLIC RELATIONS; RISK ASSESSMENT; SOCIAL MARKETING; UNITED STATES;

EID: 3342879459     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.04.015     Document Type: Conference Paper

References (17)

1. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:2003;215-224
2. P. L. 92-218, The National Cancer Act of 1971.
3. P. L. 93-352, The National Cancer Amendment 1974.
4. P. L. 95-83, The Biomedical Research Extension Act of 1977.
5. New England Journal of Medicine. 2004;. Web site. Available at: http://content.nejm.org. Accessed May 11
6. Feigl P., Blumenstein, Thompson I., et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 16:1995;150-163
7. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388
8. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin. 54:2004;8-29
9. National Cancer Institute. Cancer Information Service (CIS) Electronic Contact Record Form Data. 2003;. January to December 2003
10. National Cancer Institute, Office of Communications. Making health communications programs work. 2002;226 NCI, Bethesda, MD
11. National Cancer Institute, Office of Communications. Making health communications programs work. 2002;222 NCI, Bethesda, MD
12. Minasian L., Smigel Croker K., Ryan A., et al. Effectiveness of a media-based launch to recruit to a prostate cancer prevention trial. Control Clin Trials. 24:2003;50S
13. National Cancer Institute, Office of Cancer Communications. How the public perceives, processes, and interprets risk information findings from focus group research with the general public. 1998;NCI, Bethesda, MD
14. Pew Internet and American Life Project. The online health care revolution How the Web helps Americans take better care of themselves. 2000;26. Nov
15. Nielson Media Research/News Broadcast Network. Preliminary Report of Usage National Cancer Institute PCPT Video Release. 2004;. June 24, 2003-February 19
16. Lexis Nexis database, a division of Reed Elsevier, Inc. 2004;. Searched February
17. Dow Jones Reuters Business Interactive LLC database, trading as Factiva. 2004;. searched February